Sarepta Therapeutics
SRPT
431 hedge funds and large institutions have $5.57B invested in Sarepta Therapeutics in 2025 Q1 according to their latest regulatory filings, with 70 funds opening new positions, 146 increasing their positions, 150 reducing their positions, and 101 closing their positions.
26% more call options, than puts
Call options by funds: $102M | Put options by funds: $81.3M
3% less repeat investments, than reductions
Existing positions increased: 146 | Existing positions reduced: 150
2.53% less ownership
Funds ownership: 92.08% → 89.55% (-2.5%)
7% less funds holding
Funds holding: 465 → 431 (-34)
31% less first-time investments, than exits
New positions opened: 70 | Existing positions closed: 101
48% less capital invested
Capital invested by funds: $10.7B → $5.57B (-$5.12B)
55% less funds holding in top 10
Funds holding in top 10: 11 → 5 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$103M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$94.7M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$61.1M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$60.8M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$143M |
| 2 |
BlackRock
New York
|
-$135M |
| 3 |
O
OrbiMed
New York
|
-$117M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$101M |
| 5 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$64.9M |
SRPT Hedge Fund Activity: Q1 2025 in Review
431 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q1 2025, worth a combined $5.57B — down 48% from $10.7B a quarter earlier.
Sellers outnumbered buyers: 101 funds closed out of SRPT and 70 opened new positions — a net loss of 31 holders — while 150 trimmed existing stakes and 146 added.
The largest buyer was Morgan Stanley, adding an estimated $103M. The largest seller was Bank of New York Mellon, cutting an estimated $143M.
- 431 institutional investors held Sarepta Therapeutics (SRPT) as of Q1 2025, down from 465 in Q4 2024.
- Funds reported $5.57B of Sarepta Therapeutics stock for Q1 2025, down 48% quarter-over-quarter.
- 70 funds opened new Sarepta Therapeutics positions in Q1 2025 and 101 closed out, a net change of -31 holders.
- The largest Sarepta Therapeutics buyer in Q1 2025 was Morgan Stanley, an estimated $103M added.
- The largest Sarepta Therapeutics seller in Q1 2025 was Bank of New York Mellon, an estimated $143M sold.
Based on aggregated 13F filings for Q1 2025.